STOXIL
LOE ApproachingNDAOPHTHALMICOINTMENT
Approved
Sep 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STOXIL is an ophthalmic ointment approved in 1967 as a small-molecule NDA by GSK. The specific mechanism of action and indications are not publicly disclosed in this dataset, but the ophthalmic route suggests treatment for eye surface conditions. This is a legacy product with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely in defensive/maintenance mode rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect STOXIL's mature, LOE-approaching status with minimal hiring activity. Working on this product offers limited career growth but provides experience in defensive brand management and generic transition planning.
Product ManagerField Sales Representative
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.